When is albumin transfusion indicated in a cirrhotic patient with ascites?

Albumin Transfusion in Cirrhotic Patients with Ascites

Albumin is indicated in cirrhotic ascites patients for three specific scenarios: large-volume paracentesis >5 liters (8 g per liter removed), spontaneous bacterial peritonitis (1.5 g/kg within 6 hours then 1.0 g/kg on day 3), and hepatorenal syndrome (10-20 g daily with vasoconstrictors). 1, 2, 3

Large-Volume Paracentesis (>5 Liters)

Mandatory albumin replacement is required when removing more than 5 liters of ascitic fluid. 4, 1, 5

Dosing Protocol

• Administer 8 g of albumin per liter of ascites removed (equivalent to 100 mL of 20% albumin per 3 liters drained). 4, 1, 5
• Use 20% or 25% albumin solution—never 5% albumin, which is insufficient for this indication. 1, 2
• Infuse albumin after paracentesis completion, not during the procedure, over 1-2 hours to prevent volume overload. 1, 5

Evidence Supporting This Practice

• Without albumin, 21% of patients develop renal impairment versus 0% with albumin. 1, 6
• Albumin reduces post-paracentesis circulatory dysfunction by 60% (OR 0.40,95% CI 0.27-0.58). 6
• Albumin decreases hyponatremia by 42% and mortality by 36% compared to alternative volume expanders. 1, 5
• Post-paracentesis circulatory dysfunction severity inversely correlates with patient survival. 1

For Paracentesis <5 Liters

• Albumin is not mandatory in uncomplicated cases; synthetic plasma expanders (150-200 mL gelofusine or Haemaccel) are acceptable alternatives. 4, 1, 5
• Consider albumin at 8 g/L even for <5 liters in high-risk patients with acute-on-chronic liver failure or elevated risk of post-paracentesis acute kidney injury. 1, 5

Spontaneous Bacterial Peritonitis (SBP)

This requires a completely different weight-based dosing regimen, not volume-based. 1, 2

Dosing Protocol

• Give 1.5 g/kg albumin within 6 hours of SBP diagnosis, followed by 1.0 g/kg on day 3. 4, 1, 2
• Calculate dose using estimated dry weight, not actual weight in fluid-overloaded patients. 2
• Administer after the first antibiotic dose but do not delay beyond the 6-hour window. 2
• Both doses are essential—omitting the day 3 dose compromises outcomes. 2

Evidence Supporting This Practice

• Albumin reduces renal impairment risk by 72% (pooled RR 0.28,95% CI 0.16-0.50). 2
• Mortality decreases by 47% (pooled RR 0.53,95% CI 0.36-0.79) with albumin adjunctive therapy. 2
• Without albumin, 30% of SBP patients develop renal dysfunction, the strongest predictor of death. 2
• Patients with bilirubin >4 mg/dL or creatinine >1.0 mg/dL benefit most from this protocol. 1

Critical Distinction

• Never confuse the SBP weight-based regimen (1.5 g/kg then 1.0 g/kg) with the paracentesis volume-based dose (8 g/L)—these are completely different indications. 1, 2

Hepatorenal Syndrome

• Administer 10-20 g albumin IV daily for up to 20 days in combination with vasoconstrictors (terlipressin, midodrine/octreotide, or norepinephrine). 2, 3
• Albumin alone is insufficient; vasoconstrictors are mandatory for hepatorenal syndrome treatment. 3

When Albumin is NOT Indicated

Albumin should not be used in the following cirrhosis scenarios: 1, 2, 3

• Uncomplicated ascites managed with diuretics alone—studies show no consistent survival benefit or cost-effectiveness. 1
• Chronic hypoalbuminemia without acute decompensation—albumin as nutritional supplementation is not justified. 3, 7
• Non-SBP infections (urinary tract infections, pneumonia, cellulitis)—albumin does not reduce acute kidney injury or mortality and increases pulmonary edema risk. 1
• Routine volume expansion in stable cirrhosis—crystalloids or synthetic colloids suffice in non-acute settings. 1

Contraindications and Safety Concerns

Absolute Contraindications

• Disseminated intravascular coagulation is the only absolute contraindication to paracentesis and albumin administration. 1

Relative Cautions

• Monitor closely for fluid overload in patients with cirrhotic cardiomyopathy or baseline renal dysfunction. 2
• In one retrospective cohort, total albumin doses exceeding 87.5 g (>4 × 100 mL of 20% solution) for SBP were associated with worse outcomes, likely from fluid overload. 2
• Coagulopathy (INR ≤8.7) or thrombocytopenia (platelets ≈19×10³/μL) are not contraindications—routine correction with FFP or platelets is unnecessary and unsupported by evidence. 1, 5

Common Pitfalls to Avoid

• Do not use normal saline for volume expansion in cirrhotic ascites—it contains 154 mmol/L sodium and worsens fluid overload and ascites. 1
• Do not artificially slow paracentesis drainage rate—complete drainage to dryness in 1-4 hours is safe and evidence-based; historical concerns about circulatory collapse are disproven. 1, 5
• Do not leave drainage catheters in place overnight after completing paracentesis. 1, 5
• Do not apply the paracentesis volume-based dose (8 g/L) to SBP patients—this is a dangerous dosing error. 2
• Do not postpone albumin infusion beyond 6 hours in SBP—early administration is critical for preventing hepatorenal syndrome. 2

Post-Albumin Management

After Large-Volume Paracentesis

• Resume or initiate diuretic therapy (spironolactone 100-400 mg/day with furosemide 40-160 mg/day in a 100:40 ratio) to prevent ascites re-accumulation. 1, 5
• Enforce dietary sodium restriction to ≤2 g/day (88 mmol/day, essentially "no added salt"). 1, 5

Monitoring Requirements

• Daily serum creatinine to detect acute kidney injury. 1, 2
• Daily serum sodium to identify hyponatremia. 1, 2
• Plasma renin activity—look for >50% rise from baseline as an early marker of post-paracentesis circulatory dysfunction. 1

Medications to Avoid in Ascites Patients

• NSAIDs (indomethacin, ibuprofen, aspirin, sulindac) cause acute renal failure, hyponatremia, and diuretic resistance. 1
• ACE inhibitors and angiotensin-II receptor blockers precipitate arterial hypotension and renal failure. 1
• α₁-adrenergic blockers (prazosin) impair renal sodium retention and worsen ascites. 1
• Aminoglycosides increase renal failure risk; reserve for infections untreatable with other agents. 1

Transplant Evaluation

• Development of ascites constitutes an indication for liver transplantation evaluation, reflecting a poor prognosis with approximately 50% two-year survival. 1, 5
• All patients with SBP should be considered for transplant referral. 4